Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al

• Thomas Blankenstein,
• Lena Immisch,
• George Papafotiou,
• Oliver Popp,
• Philipp Mertins,
• Gerald Willimsky

Affiliations

Thomas Blankenstein

Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Lena Immisch

Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

George Papafotiou

Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Oliver Popp

Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Philipp Mertins

Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Gerald Willimsky

Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany